Inside Precision Medicine April 16, 2024
Add multiple sclerosis to the list of conditions the new weight loss drugs may help treat. Novel diabetes drugs like Ozempic and Wegovy initially showed promise in weight loss and have since been marketed and widely used for this indication. However, a new study based on real world data (RWD) describes a possible protective effect against multiple sclerosis (MS) for some of these medications, including semaglutide (Novo Nordisk’s Ozempic, Wegovy, and Rybelsys) and dulaglutide (Eli Lilly’s Trulicity).
Repurposing such drugs for this disease can only be much welcomed news for the MS community, it could also be a further boost for the thriving global market for new anti-obesity medications. Goldman Sachs Research has estimated this market had already reached $6...
Today's Sponsors
Today's Sponsor